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2La radioterapia stereotassica body
Stereotactict body radiotherapy (SBRT)
Brief description of my projects and end-points of my work:
I year
 Definition of clinical indication for SBRT and study of treatment
modality procedures.
 Evaluation and definition of the best immobilization system devices.
 Definition of the best imaging techniques for treatment planning.
During my first year of study I worked at Division of  Radiotherapy
(Policlinico S. Orsola-Malpighi, University of Bologna, Dir. Prof. Enza
Barbieri); my goals have been achived, particularly it was written the first
protocol (radiotherapy indication: SBRT) of our Division of Radiotherapy
for primary and/or metastatic hepatic tumour.
During my first year I started an active collaboration with Radiotherapy
3Department of Heidelberg University- Hospital (Germany) where I worked
for a short period of time to learn the principles and clinical application of
IMRT-SBRT and IGRT.
II year
 Definition of treatment planning modality of selected patients affected
by other types than hepatic tumour.
 Evaluation of different fractionation and dosimetry evaluation.
During the second year my research has been implemented with the study of
a different categories of patient, particularly focusing on the study of
isolated lymph-nodes recurrence in prostate cancer treated with two different
types of SBRT modality: LINAC vs SBRT with Cyberknife.
My work has been carried on collaboration with the Division of
Radiotherapy of University of Bologna and the Division of Radiotherapy of
European institute of oncology, IEO; Milan; Dir. Prof. Roberto Orecchia.
III year
 Presentation of material and methods, results and conclusions of a
4short group of patients treated with SBRT: evaluation of treatment
efficacy (local control rate) and toxicity.
During the last year I worked in collaboration with Division of Radiotherapy
of University of Bologna and Division of Radiotherapy  of European
institute of oncology, IEO; Milan. For my study I evaluated the patients
affected by isolated recurrence in gynecological cancer that were candidated
to radiotherapy treatment.
51. Introduction
Stereotactic body radiotherapy (SBRT) refers to the precise irradiation of an
image-defined extracranial lesion using a small number (one to five) of high-
dose fractions. It has developed from intracranial single-fraction stereotactic
radiotherapy (also known as radiosurgery), which is conceptually different
from conventionally fractionated radiotherapy (CFR). In its fractionated
form, SBRT shares characteristics of both radiosurgery and CFR. The high
doses per fraction strive towards an ablative tumor effect, whereas the use of
modest fractionation implies the need to allow some normal tissue recovery.
The safe delivery of very large doses per fraction requires effective patient
immobilisation, precise target localization (which may involve fusion of
different imaging modalities), sophisticated planning software, accurate
treatment delivery and the ability to produce a steep isodose gradient outside
the target volume. In addition, extracranial lesions
pose further challenges to treatment delivery due to interand intrafraction
tumor and critical organ motion. Until recently this has limited the ability to
deliver stereotactic radiotherapy to targets outside the brain. However,
advances in image guidance have allowed treatment systems to account for
such motion and, consequently, the use of SBRT is increasing (18).
62. History
Stereotactic surgery was first described by Horsley and Clarke in 1906. They
developed a method of locating deepseated brain lesions by assigning
coordinates in three planes to neuroanatomical structures, based on cranial
landmarks. In 1947, Spiegel et al. introduced frame based stereotaxy using a
plaster head cap known as a stereoencephalatome, and a three-dimensional
coordinatesystem relative to this. Lars Leksell, a Swedish neurosurgeon, was
the first person to marry the two developing fields of stereotaxy and
radiation therapy, and introduced the term‘radiosurgery’ in 1951. He used a
rigid metal stereotactic head frame fixed to the skull. Small intracranial
targets were localised relative to the frame and radiation was delivered in a
single high-dose fraction. The technique initially used 250 kV X-rays, but in
1967 the first Gamma Knife prototype was developed, using 179 cobalt-60
sources focused on the target. Since then, the Gamma Knife has become
widely used for stereotactic radiosurgery, with sub-millimetre total system
accuracy. However, Gamma Knife stereotactic treatment is largely limited to
intracranial targets. The 1980s saw the adaptation of linear accelerators
(linacs) for intracranial stereotactic delivery, again using rigid stereotactic
head frames, and specialist dosimetry software, e.g. X-Knife (Radionics,
7Boston, MA, USA). In 1995, Hamilton et al. proposed a method of
delivering linacbased stereotactic radiotherapy to spinal lesions using a
prototype rigid ‘extracranial stereotactic frame’ and associated three-
dimensional coordinate system. Immobilisation was achieved by
transcutaneous frame fixation to spinous processes superior and inferior to
the target. They reported an overall treatment accuracy of 2 mm, but the
technique was time-consuming, cumbersome and limited to the delivery of
single fractions. Also, as with intracranial immobilisation methods, this
approach relied upon a fixedrelationship between target and bony anatomy.
Around the same time, Lax et al. developed a stereotactic body frame,
which, together with a vacuum bag, immobilised the patient from head to
mid-thigh. They found the set-up reproducibility for liver and lung lesions to
be within 5–8 mm for 90% of the patients. Many stereotactic radiotherapy
systems today use a similar set-up with body frame immobilisation.
However, for most extracranial sites the position of the tumor does not enjoy
a fixed relationship relative to the external body contour, and can move both
between and during each fraction of radiotherapy. An external body frame
alone is therefore not sufficient to ensure accurate delivery of radiation to
the target. Lax et al.showed that diaphragmatic movements could be reduced
to 5–10 mm by applying a pressure on the Stereotactic surgery was first
8described by Horsley and Clarke in 1906. They developed a method of
locating deepseated brain lesions by assigning coordinates in three planes to
neuroanatomical structures, based on cranial landmarks. In 1947, Spiegel et
al. introduced framebased stereotaxy using a plaster head cap known as a
stereoencephalatome, and a three-dimensional coordinate system relative to
this.
Lars Leksell, a Swedish neurosurgeon, was the first person to marry the two
developing fields of stereotaxy and radiation therapy, and introduced the
term‘radiosurgery’ in1951. He used a rigid metal stereotactic head frame
fixed to the skull. Small intracranial targets were localised relative to the
frame and radiation was delivered in a single high-dose fraction. The
technique initially used 250 kV X-rays, but in 1967 the first Gamma Knife
prototype was developed, using 179 cobalt-60 sources focused on the
target. Since then, the Gamma Knife has become widely used for stereotactic
radiosurgery, with sub-millimetre total system accuracy . However, Gamma
Knife stereotactic treatment is largely limited to intracranial targets.
The 1980s saw the adaptation of linear accelerators (linacs) for intracranial
stereotactic delivery, again using rigid stereotactic head frames, and
specialist dosimetry software, e.g. X-Knife (Radionics, Boston, MA, USA).
In 1995, Hamilton et al. proposed a method of delivering linacbased
9stereotactic radiotherapy to spinal lesions using a prototype rigid
‘extracranial stereotactic frame’ and associated three-dimensional coordinate
system. Immobilisation was achieved by transcutaneous frame fixation to
spinous processes superior and inferior to the target. They reported an
overall treatment accuracy of 2 mm, but the technique was time-consuming,
cumbersome and limited to the delivery of single fractions. Also, as with
intracranial immobilisation methods, this approach relied upon a fixed
relationship between target and bony anatomy. Around the same time, Lax et
al. developed a stereotactic body frame, which, together with a vacuum bag,
immobilised the patient from head to mid-thigh. They found the set-up
reproducibility for liver and lung lesions to be within 5–8 mm for 90% of the
patients. Many stereotactic radiotherapy systems today use a similar set-up
with body frame immobilization ( Fig.1 ). However, for most extracranial
sites the position of the tumor does not enjoy a fixed relationship relative to
the external body contour, and can move both between and during each
fraction of radiotherapy. An external body frame alone is therefore not
sufficient to ensure accurate delivery of radiation to the target. Lax et al.
showed that diaphragmatic movements could be reduced to 5–10 mm by
applying a pressure on the images, but largely rely on implanted fiducials.
Percutaneous fiducial insertion can be technically difficult, especially in the
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upper abdomen, where it may be necessary to pass through other organs to
reach the target lesion. In the lung, there have been concerns about the
complication rates observed with percutaneous fiducial implantation. A
25–40% incidence of pneumothorax requiring drainage has been reported .
However insertion techniques are improving. In a recent series described
below, Van der Voort van Zyp et al. used either a percutaneous or a vascular
approach, depending on the perceived risk of pneumothorax.
Only four of 70 patients developed pneumothorax, and in only one of these
cases was a chest drain necessary. ‘Xsight Lung’ is a feature of the
CyberKnife SBRT system (see below), which allows the tracking of certain
peripheral lung tumors without the need for implanted fiducials (18).
11
Fig.1 (A and B)
A: Body frame immobilization device
B: Body frame immobilization device and laser alignement
12
3. Fractionation and Radiobiology
In CFR, the tumor volume is irradiated together with a margin to account
for tumor and organ motion, and inaccuracies of planning, set-up and
delivery. The total dose is limited by the tolerance of normal tissue within,
or close to, the planning target volume (PTV) ( Fig. 2). The therapeutic
benefit achieved with dose fractionation has been recognized for over 100
years. Conventional fractionation has emerged as a result of these early
clinical observations, and subsequent changes have been driven largely by
clinical outcomes. The development of radiobiological concepts, such as the
linear quadratic model and Withers’ ‘4 Rs’ of radiotherapy , has led to
further understanding of the tissue effects of fractionation. By contrast,
radiosurgery exploits the potent radiobiological effect of large single doses
of radiation, which transcends the considerations proposed by Withers.
Considerable dose inhomogeneity within the target volume is standard
practice, due to the internal dose gradient achieved by using a low
prescription isodose (commonly 40–60% with Gamma Knife radiosurgery).
There is some evidence to suggest that, rather than being a problem,
13
carefully planned target dose inhomogeneity may enhance the tumoricidal
effect. Fractionated SBRT sits somewhere between the extremes of CFR and
radiosurgery. Large doses per fraction are used and a moderate internal dose
gradient achieved, with a typical prescription isodose of 60–80% (Fig.3).
Unlike intracranial radiosurgery, inter- and intrafraction movement of tumor
and organs at risk is a big problem. This increases the risk of irradiating
normal tissue (and missing the tumor) during treatment. Also, the
overwhelming clinical experience of treating extracranial tumors is with
conventional fractionation. For these reasons, moving away from
fractionation completely is a big step for many extracranial sites. The linear
quadratic model and its derivatives can help clinicians to predict tissue
response to altered fractionation regimens. However, there has been concern
that it does not accurately predict tumor cell response at the higher doses per
fraction seen with stereotactic treatment. It is not clear to what extent modest
fractionation (two to five fractions) differs from a single fraction with
respect to tumor response and normal tissue effects. Unsurprisingly,
therefore, there has been a large variation in dose and fractionation across
SBRT series published to date. Although some SBRT centres adopt a ‘single
large fraction’ strategy for many patients, other centres would prefer to
fractionate in similar cases. Current regimens have in many cases been
14
derived empirically, often the result of cautious dose escalation, as
illustrated by phase I trials in non-small cell lung cancer (NSCLC) , liver
metastases and pancreatic carcinoma (18).
Fig.2
GTV (gross tumour volume), CTV (clinical target volume), PTV (planning
target volume).
GTV
CTVPTV
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Fig. 3
Exemple of SBRT treatment planning
4. Overview of Stereotactic Body Radiotherapy Systems
The term radiosurgery or stereotactict radiosurgery is used for
stereotactically guided conformal irradiation of a defined target volume in a
single session (19).
SBRT can be delivered with Gamma Knife modified LINAC radiosurgery
systems (including Cyberknife ) and image guided radiotherapy system,
tomotherapy or proton beam system.
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The term stereotactict radiation therapy refers to stereotactically guided
delivery of highly conformal radiation to a defined target volume in multiple
fraction, tipically using noninvasive positioning techniques.
Adding intensity modulated radiation therapy (IMRT) to the nomenclature
can further complicate or confuse the terminology. Any radiation treatment
plan that uses individual  treatment beams that irradiate only part of the
target at a time is IMRT. Strictly speaking, multiple isocenter radiosurgery
(of a single target volume) meets the criteria for IMRT or stereotactic IMRT
(19).
A number of modern linacs with on-board imaging capabilities meet the
basic image guidance requirements for delivering SBRT, e.g. Varian Trilogy
(Varian Medical Systems, Palo Alto, CA, USA) ( Fig.4) and Elekta Synergy
(Elekta, Stockholm, Sweden) . A micro multileaf collimator can be added to
produce the required degree of conformality for stereotactic plans. More
recently there has been the introduction of linacs fully adapted as integrated
stereotactic delivery systems. Novalis TX has a Varian Trilogy linac base
with micro (2.5 mm) multileaf collimator. Other features include the
BrainLAB Other features include the BrainLAB ‘‘ExacTrac X-ray 6D’’
system (Fig.5) providing near real-time image guidance with six degrees of
freedom, a corresponding robotic treatment couch, and associated software
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(BrainLAB, Munich, Germany). Elekta Axesse is a similar integrated
system. The TomoTherapy Hi-Art System (TomoTherapy, Madison, WI,
USA) has a ring gantry as used in diagnostic computed tomography scanners
and delivers helical intensitymodulated radiotherapy (IMRT) via thousands
of small beamlets. Couch movement is continuous during radiation delivery.
The system has on-board image guidance with megavoltage computed
tomography. CyberKnife (Accuray, Sunnyvale, CA, USA) is an
imageguided robotic radiosurgery system.Acompact 6 MVX-band linac is
mounted on a six-joint robotic arm. This provides flexibility in beam pattern
generation, allowing the system to produce very conformal, non-isocentric
plans. As with Novalis TX, a robotic couch with six degrees of freedom and
near real-time kV image guidance also feature ( 18).
18
Fig.4
Linac Trilogy By Varian
19
Fig.5
BrainLAB ‘‘ExacTrac X-ray 6D’’
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4.1 LINAC
SBRT is the use of high doses of radiation to small targets outside of the
brain. SBRT began in the 1990s, when new devices were developed to
dampen respiratory excursion and use imaging technologies to verify a
target's location within the patient while the patient is on the radiation
treatment table , allowing the radiation oncologist to more accurately
account for internal target and organ movement . The term ‘stereotactic’
implies the use of a system of 3-dimensional coordinates to localize a region
of interest within the body, using either internal or external reference
markers. Immobilizing body frames use external references whereas newer
systems use either “on-board imaging” or internalized fiducial markers.
While different investigators may use varying definitions, the U.S. Medicare
statutes define SBRT as consisting of 1–5 treatments. In some centers,
SBRT is performed on the same treatment platform as conventional RT, but
with additional “on board” imaging devices to verify patient positioning and
intensity modulation to conform dose to the target. For instance, a cone-
beam CT can be obtained while a patient is lying on the treatment table
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about to be treated and the CT images used to compare to the original CT-
based radiation plan to assure congruency of the planned versus actual
patient position . Some cone-beam CT systems utilize megavoltage (MV)
energies using the same linear accelerator source as the therapeutic radiation
doses emitted afterwards (Siemens Medical Solutions, Inc., Concord, CA
and TomoTherapy Inc., Middleton, WI). Other systems provide higher
resolution cone-beam CTs with kilovoltage (kV) energies (Varian Medical
Systems Inc., Palo Alto, CA and Elekta AB, Stockholm, Sweden) ( Fig. 9).
Alternatively, small, radio-opaque fiducial markers can be placed directly
into the tumor or surrounding tissues. The fiducials are then localized on two
dimensional (2D) kV X-rays and the spatial relationship between the
markers and between the markers and 2D bony anatomy informs the viewer
of the internal location of the target and position of the patient. The real-time
tumortracking (RTRT) system, developed at the Hokkaldo University
School of Medicine in Japan, uses X-rays obtained every 0.03 s to localize
fiducial markers and rapidly turns off the radiation beam with only 0.03 s of
lag time when the target is outside of the radiation beam . SBRT has met
with promising success in treating early T1-2N0 non-small cell lung cancers
, renal cell carcinoma ,hepatocellular carcinoma , and low and intermediate
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risk prostate cancer , particularly in medically inoperable patients. SBRT has
also become a routine way to treat lung, spine, and liver metastases (18).
RapidArc (RA) radiotherapy is a new technique that use intensity modulated
arc therapy and IGRT. The plans was generated using two coplanar arcs of
360° optimized simultaneously with a beam energy of 6 MV.  The RA
technique uses continuous variation of the instantaneous dose rate, MLC leaf
positions and gantry rotational speed to optimaze the dose distribution. The
collimator angle was kept fixed and set to 20° for all patients.
The dose calculations and optimizations were performed using the Eclipse
treatment planning system (version 8.6) for a Trilogy equipped with the
Millennium multileaf collimator 120 leaves (leaf width at isocenter of 5 mm
in the central 20 cm part of the field, 10 mm in the outer 2x10 cm). The
maximal dose rate was set to 600 MU/min. Dose calculation was performed
with the AAA algorithm using a grid of 2.5 mm (20).
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Fig. 9
Cone-beam CTs with kilovoltage (kV) energies
4.2 Robotic SBRT
Robotic SBRT uses the same source of radiation as conventional external
beam radiotherapy, but the linear accelerator is mounted onto a robotic arm
with more degrees of freedom than the circular 360 degree path around the
patient on conventional accelerators. The robotic arm is similar to ones used
on car manufacturing assembly plants and can move rapidly enough to
match changes in a target's position detected by kV X-ray imaging, such as
when a lung tumor moves during the respiratory cycle. The Cyberknife
robotic arm device (Accuray Inc., Sunnyvale, CA) allows for the delivery of
24
an increased number of angles of radiation entry into the body and thereby
allows a greater multiplicity of converging beams (100–300) .
By comparison, conventional external beam radiotherapy typically employs
only 1–9 stationary beams. The technologic advantage of the multiplicity of
beams and the stereotactic tracking allows robotic radiosurgery to employ a
smaller margin around a target and therefore less normal tissue receives high
doses of radiation. Instead of adjusting the position of the linear accelerator
to accommodate internal organ movement like the Cyberknife, the Novalis
TX system (BrainLAB) also uses robotic technology to automatically adjust
the patient's position. The Novalis system obtains orthogonal 2D X-rays
while the patient is on the treatment machine to match digitally
reconstructed radiographs derived from the original radiation planning CT.
Registration of the two data sets drives the robotic adjustment of the
treatment table to bring into agreement the actual and the planned patient
position. Placement of the fiducials into the lung, liver, or other locations
can be achieved through percutaneous, CT-guided insertion of the seeds
directly to the tumor, typically by interventional radiologists. Alternatively,
fiducials can be placed directly into the lung through an endobronchial
approach to reduce the pneumothorax risk with a percutaneous approach .
Thus there are a number of radiotherapy systems capable of performing
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SBRT, and no one system can be considered uniformly superior to another .
The Novalis, Cyberknife, and RTRT systems each provide rapid
fluoroscopic imaging to localize and track fiducial markers, but the
Cyberknife lacks 3D information and morbidity can result from internal
fiducial placement. The cone-beam CT based systems provide 3D
information regarding target position, but the lag time between the CT and
treatment start can be minutes in duration and thus there is limited ability to
track a target (20).
5. Planning and target volume definition
The planning target volume (PTV) margins used to account for this residual
motion of the gross tumour volume (GTV) will tipically range from 5 to 10
mm. The word “stereotactic” has heretofore usually implied that some sort
of external reference markers indexed to internal structures facilitate internal
target relocalization, although the definition has loosened to include system
of image-guided radiation therapy. Indeed, implicit in the current definition
of SBRT is the assumption that some form of IGRT will be used for
treatment delivery. Most reports describing SBRT published to date have
employed high-energy photons (x-rays) as the source of therapeutic radiation
26
although other particles could also be used. There is no absoluted standard
for the combination of beam or arc angles ideal for any given clinical
situation, and each case can present unique challenges. In general to achieve
a tightly focused high dose distribution within the PTV and rapid dose
falloff outside the PTV, a combination of multiple (often seven to 10)
noncoplanar beams or multiple arcs are required. Intensity modulation
across the individual beams or arc segments can be incorporated within
SBRT (19) ( Fig. 6).
Fig.6
Example of SBRT treatment planning and dosimetry
27
6. SBRT: clinical indications
The best indication of SBRT was the treatment of “Oligometastatic” disease:
it is a term used to describe a disease state in which limited sites of
metastatic disease may still be addressed definitively with local therapy.
Conceptually, this term applies to at least three general situations in which
local therapy may have a benefit. SBRT is one of several treatment
modalities capable of treating oligometastatic disease particularly for liver
tumor (primary and metastatic disease), lung tumor (primary or metastasic
disease), pancreas cancer, kidney cancer, prostate cancer (primary treatment
or local recurrence or metastatic disease), spine metastases, gynecological
cancer (20).
6.1 SBRT in gynecologic oncology
To date, SBRT has been used for gynecologic malignancies in the
treatment of macroscopic pelvic and periaortic lymph nodes and
oligometastatic disease. Image guided therapy using cone-beam CT or
28
fiducial tracking is highly advantageous for gynecologic malignancies to
account for the significant degree of uterine movement due to bladder and
rectum filling/emptying and because of the 45–60% tumor regression seen
during conventional RT (before SBRT boosts) ( 20).
In the pelvis, fiducials can be inserted into the cervix, paravaginal
and parametrial tissues by gynecologic oncologists or radiation
oncologists during an outpatient pelvic examination. Fiducials can
fall out of the cervix or move slightly relative to the other fiducials
thus introducing some small errors . After that a radiation oncologist
verifies the position of the fiducials on the planning CT and on 2D X-rays
before the first SBRT treatment begins (20).
7. The role of FDG-PET/CT in the different gynecological
malignancies
Of the various gynecological neoplasms, endometrial, cervical and ovarian
cancer give the most cause for concern, both epidemiologically and in terms
of the evolution of the pathology. Whilst prevention remains the main
strategy to reduce cancer incidences, imaging is central to work-up and
appropriate management of patients after diagnosis. Cross-sectional imaging
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techniques such as ultrasound (US), computed tomography (CT) and
magnetic resonance imaging (MRI), which can show anatomical detail and
morphological changes in the female genitourinary tract to good advantage,
have been used to detect and monitor cases of gynecological cancer.
Positron emission tomography (PET) with fluorodeoxyglucose (FDG)
instead shows functional changes not easily detected using the other
crosssectional imaging techniques. The fusion of FDG-PET with CT allows
anatomical localisation of functional abnormalities in the female genital tract
and thus the detection of gross disease in many malignant conditions both
within and outside the pelvis (2) (Fig. 7 and 8).
Fig.7
Positive Pelvic lymph-node with 18FDG-PET/CT
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Fig. 8
Positive Para-aortic lymph-node with 18FDG-PET/CT
31
7.1 Cervical cancer
Loft et al., of the PET and Cyclotron Unit 3982, Department of Clinical
Physiology and Nuclear Medicine, Centre of Diagnostic Investigations,
Rigshospitalet, Copenhagen University Hospital, Denmark, investigated the
clinical value of FDG-PET/CT as a supplement to the FIGO staging system
in patients with cervical cancer stage ≥1B.
The prospective study included 120 consecutive patients. After staging, a
whole-body FDG-PET/CT scan was performed, on the basis of which
patients were referred for radical hysterectomy including lymph node
dissection or combined chemotherapy/radiation therapy. The treatment
results were compared to histopathological findings and/or follow-up.
Twenty-seven patients underwent radical surgery, of whom four had FDG-
PET/CT scans revealing pathological foci in the pelvis. Three (11%) were
true-positive; one was false-positive. Twenty-two patients had true-negative
pelvic lymph nodes. One patient had a false-negative node. FDG-PET/CT
scanning had a positive predictive value (PPV) of 75%, a negative predictive
value (NPV) of 96%, sensitivity of 75% and specificity of 96%. Of the total
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study population of 119 patients, 15 were found to have true-positive scans
for paraaortal nodal disease, whilst the true-negatives totalled 103. These
results yielded PPV of 94%, NPV of 100%, sensitivity of 100% and
specificity of 99%. FDG-PET/CT scans showed distant metastases in 19
patients, of whom ten were true-positive and nine were false-positive cases.
The remaining 100 patients were considered true-negative for distant
metastases, and in these patients, the evaluation showed the following
values: PPV 63%, NPV 100%, sensitivity 100% and specificity 94%. The
authors conclude that whole-body FDG FDG-PET/CT scanning for newly
diagnosed cervical cancer FIGO stage ≥1B has high sensitivity and
specificity and may usefully supplement FIGO staging.
Yen et al., of the Molecular Imaging Center and Department of Nuclear
Medicine, Chang Gung Memorial Hospital Linkou Medical Center, 5 Fu-
Shin Street, Kueishan, Taoyuan, Taiwan, set out to identify prognostic
factors, including FDG-PET parameters, in patients with previously
untreated squamous carcinoma of the uterine cervix and MRI- or CT-defined
pelvic or paraaortic lymph node (PLN or PALN) metastasis . FDG-PET
scans were performed for primary staging. Prognostic variables were
investigated by univariate and multivariate analyses. Five-year recurrence-
free and 5-year overall survival rates (RFS and OS) were evaluated using the
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Kaplan–Meier method. A total of 70 patients (54 patients with FIGO stage I
or II, 16 patients with stage III or IV) were eligible. Duration of follow-up
ranged from 26.1 to 71.6 months. In multivariate analysis, FIGO stage ≥III
emerged as a significant prognostic factor for RFS and for OS (both
p=0.008). In addition, standardised uptake value (SUVmax) for PALN (with
3.3 as the cut-off) was significantly associated with OS (p=0.012) and
marginally associated with RFS (p=0.078). SUVmax ≥3.3 at PALN or FIGO
stage ≥III was significantly associated with both recurrence (RFS: HR=4.52,
95% confidence interval=1.73– 11.80) and death (OS: HR=6.04, 95%
confidence interval= 1.97–18.57). The authors concluded that SUVmax ≥3.3
for PALN and FIGO stage ≥III were significant adverse factors in patients
with primary squamous cervical carcinoma and PLN or PALN metastasis
detected by CT or MRI. Bjurberg et al., of the Department of Oncology,
Lund University Hospital, Sweden, remark that today’s conventional
imaging modalities do not readily visualise the full extent of the disease in
cases of cervical cancer . They report the interim analysis of an ongoing
prospective study evaluating the potential role of FDG-PET with software
fusion with CT images in three different clinical stages of cervical cancer.
Group 1 comprised ten patients with early stage cervical cancer submitted to
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FDG-PET 6 months after surgery. Group 2 comprised 17 patients with
locally advanced cervical cancer who underwent FDG-PET as part
of the staging procedure. Group 3 was made up of 12 patients with verified
relapse and three with strongly suspected relapse who underwent FDG-PET
before starting any therapy. The results of FDG-PET were compared with
those of standard conventional work-up. All patients were followed up for at
least 6 months. All the FDG-PET scans in group 1 were true-negative. In
group 2, FDG-PET detected metastases in new locations in four patients and
a synchronous pulmonary carcinoma in one patient, resulting in a
change in treatment plan in four patients. One false-negative FDG-PET
result was recorded. In group 3, three patients’ treatment plans were changed
in the light of the FDG-PET results. The authors conclude that FDG-PET
provides crucial information in the pre-treatment staging procedure in
patients with locally advanced or relapsed cervical cancer. However,
FDG-PET scans performed 6 months postoperatively offered no clinical
benefit in the follow-up of this study’s small group of patients with early
cervical cancer. Boughanim et al., of the Department of Surgery, Institut
Gustave Roussy and University Paris Sud, Villejuif, France, compared the
histological findings from complete paraaortic lymphadenectomies
performed in 38 patients under treatment for stage IB2/II cervical carcinoma
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who had no paraaortic uptake on FDG-PET/CT . Patients treated for stage
IB2/II cervical cancer between 2004 and 2006 underwent MRI of the
abdomen and pelvis and FDG-PET/CT. Patients with no paraaortic
abnormalities were treated with external pelvic radiation therapy and
concomitant chemotherapy followed by uterovaginal brachytherapy.
Paraaortic lymphadenectomy was then performed. The FDG-PET/CT
images were reviewed by two nuclear medicine specialists. Three patients
had histological evidence of paraaortic involvement (metastatic nodes with
capsular rupture in the paraaortic area), leading to an NPV of 92% for
paraaortic nodal involvement. The authors conclude that the histological
demonstration of paraaortic node involvement in three of these 38 patients
who had no paraaortic uptake on FDG-PET/CT imaging means that failure
to carry out histological examination of the paraaortic area when
determining the fields for radiation therapy in stage IB2/II cervical cancer
would result in 8% of patients with paraaortic nodal involvement being
overlooked. Yildirim et al., of the Department of Gynecologic Oncology,
Aegean Obstetrics and Gynecology Training and Research Hospital, Izmir,
Turkey, set out to evaluate the usefulness of integrated FDG-PET/CT for
establishing paraaortic nodal status and to test whether FDG-PET/CT
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results can alter the management strategy adopted in locally advanced
cervical cancer (LACC) patients with negative conventional CT findings.
Sixteen patients with locally advanced (FIGO stage IIB–IVA) cervical
squamous cancer (median age 48.7 years, range 42–67 years) and negative
conventional CT findings were eligible to enter this prospective study. All
the patients underwent FDG-PET/ CT scans followed by extra-peritoneal
surgical exploration for paraaortic lymphadenectomy. The accuracy,
sensitivity, specificity, PPV and NPV of the FDG-PET/CT for paraaortic
lymph node metastasis were then calculated on the basis of the
histopathological findings and found to be 75%, 50%, 83.3%, 50% and
83.3%, respectively. The treatment was modified in 4 (25%) of the 16
patients: they underwent extended-field radiotherapy in combination with
cisplatin chemotherapy instead of standard pelvic-field radiotherapy in
combination with cisplatin chemotherapy. Despite the small size of the
sample, the authors conclude that FDG-PET/CT is effective in the evaluation
of LACC with negative CT findings. It may help in planning the
management of these patients, and especially in selecting the radiation field.
However, they acknowledge that larger controlled studies need to be carried
out before FDG-PET/ CT can be recommended as an alternative to pre-
treatment surgical staging. They also remark that although cervical cancer
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could be eradicated through the development of effective HPV vaccination
programmes, this would take at least 40–50 years, and that for the
foreseeable future cervical cancer will continue to be a major public health
problem worldwide. Kitajima et al., of the Department of Radiology,
Dokkyo University School of Medicine, Tochigi, Japan, recently compared
the accuracy of integrated FDG-PET/CT with that of PET alone for
diagnosis of suspected recurrence of cervical cancer. Fifty-two women with
suspected recurrence of previously treated histopathologically confirmed
cervical cancer underwent PET/CT. PET alone and integrated PET/CT
images were evaluated by two different experienced radiologists who
reached a consensus for each investigation. A final diagnosis was confirmed
by histopathology, radiological imaging and clinical follow-up for
over 1 year. Patient-based analysis showed that the sensitivity, specificity
and accuracy of PET/CT were 92.0% (23/25), 92.6% (25/27) and 92.3%
(48/52), respectively, whilst for PET alone the corresponding figures were
80.0% (20/25), 77.8% (21/27) and 78.8% (41/52). PET/CT resolved the
false-positive PET results attributable to hypermetabolic activity of
benign/inflammatory lesions and physiological variants and was able to
detect lung metastasis, local recurrence, peritoneal dissemination, paraaortic
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lymph node metastasis and pelvic lymph node metastasis missed by PET
alone. However, even FDGPET/ CT was unable to detect tiny local
recurrence and lymph node metastasis. FDG-PET/CT is a useful
complementary tool for obtaining good anatomical and functional
localisation of sites of recurrence during follow-up of patients with cervical
cancer (2).
7.2 Cancer of the uterus
Sorosky, of the Department of Obstetrics and Gynecology, Hartford
Hospital, University of Connecticut, CT, USA, recently reviewed the
epidemiology, prevention, diagnosis, treatment and prognosis of endometrial
carcinoma, remarking that although the incidence of the disease has
remained stable, the death rate has more than doubled over the past two
decades . Precursor lesions of complex hyperplasia with atypia are
associated with an endometrial carcinoma in over 40% of cases. The
proportion of obese women with endometrial cancer is increasing. The
incidence of endometrial cancer in white women is twice that recorded in
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African-American women but, stage for stage, African- American women
have a less favourable prognosis. Preoperative imaging cannot accurately
assess lymph node involvement, whilst gross examination of the depth of
myometrial invasion lacks the sensitivity, specificity and PPV or NPV
needed to select women in whom lymphadenectomy can safely be omitted
from the surgical procedure. In the absence of ideally non-invasive
preoperative testing, surgical staging remains the most accurate method of
determining the extent of the disease. The past two decades have seen an
increase in surgical staging and a decrease in postoperative adjuvant pelvic
radiation therapy. Women with a history of hereditary non-polyposis
colorectal cancer are at increased risk of endometrial cancer. Conservative
treatment to allow for childbearing is possible in certain situations.
Women with endometrial cancer should be managed by physicians
experienced in the treatment of this disease. The validity of FDG-PET for
the preoperative evaluation of endometrial cancer has been studied by
Suzuki et al., of the Department of Obstetrics and Gynecology, Yokohama
City University School of Medicine, Yokohama, Japan; these authors
examined 30 patients with endometrial cancer and compared PET, CT, MRI
and postoperative pathological findings . They found that FDG-PET could
easily identify primary lesions, displaying a higher sensitivity (96.7%) than
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CT/MRI (83.3%). In contrast, in the evaluation of retroperitoneal lymph
node metastasis, FDG-PET was able to detect none of five cases of lymph
node metastatic lesions of up to 0.6 cm in diameter, although it showed a
higher specificity (100%) than CT/MRI (85.7%). The sensitivity of FDG-
PET for the detection of extrauterine lesions excluding retroperitoneal lymph
nodes was 83.3% and was superior to that of CT/MRI (66.7%), although no
difference in specificity emerged between the two modalities (both 100%).
The diagnostic ability of FDG-PET was limited if the technique was used
alone, but it was able to clarify, for example, the nature of extrauterine
lesions whose significance could not be determined on CT/MRI. However,
given that FDG-PET was also unable to detect any lymph node metastasis
under 1 cm in diameter, the authors conclude that a negative result on
FDG-PET for lymph node metastasis does not justify omitting
retroperitoneal lymph node dissection for the precise surgical staging of
endometrial cancer. To evaluate the accuracy of FDG-PET/CT vs FDG-PET
alone in the diagnosis of suspected endometrial cancer recurrence, Kitajima
et al., of the PET Center, Dokkyo Medical University Hospital, Mibu,
Shimotuka, Tochigi, Japan, enrolled 30 women who had undergone primary
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surgery for histopathologically confirmed endometrial cancer with suspected
recurrence . FDG-PET and integrated FDG-PET/CT images were evaluated
by two different experienced radiologists who reached consensus
for each examination. Recurrence (suspected on the basis of clinical,
cytological, biochemical and/or radiological findings) was confirmed by
histopathology, other imaging and clinical follow-up for longer than 1 year.
The statistical significance of differences between FDG-PET and FDGPET/
CT was determined by the McNemar test. Patient based analysis showed that
the sensitivity, specificity and accuracy of FDG-PET/CT were 93% (14/15),
93% (14/15) and 93% (28/30), respectively, whereas the corresponding data
for FDG-PET were 80% (12/15), 80% (12/15) and 80% (24/30) (p=0.479,
p=0.479 and p=0.134, respectively). The CT component of FDG-PET/CT
analyses resolved false-positive FDG-PET results attributable to
hypermetabolic activity of benign inflammatory lesions and physiological
variants and, moreover, detected lung metastasis and paraaortic lymph node
metastasis that FDG-PET missed. However, even FDG-PET/CT was unable
to detect tiny paraaortic lymph node metastasis. The authors conclude
that integrated FDG-PET/CT is a useful complementary tool for obtaining
good anatomical and functional localization of sites of recurrence during
follow-up of patient with endometrial cancer. To compare FDG-PET/CT
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with MRI in the preoperative detection of primary lesions and lymph node
and distant metastases in patients with uterine cancer, Park et al., of the
Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan
Medical Center, Songpa-Ku, Seoul, South Korea, enrolled 53 women with
uterine cancer who underwent preoperative work-up based on MRI and
FDGPET/ CT scans and surgical staging including pelvic and/or
paraaortic lymph node dissection between October 2004 and June 2007.
Pathological data from surgical staging were compared with the preoperative
MRI and FDG-PET/ CT results. For area-specific analysis, lymph nodes
were divided into three groups: paraaortic, right pelvic and left pelvic. In the
detection of primary lesions, MRI and FDGPET/ CT showed no differences
in sensitivity (91.5% vs89.4%), specificity (33.3% vs 50.5%), accuracy
(84.9% vs 84.9%), PPV (91.5% vs 93.3%) or NPV (33.3% vs 37.5%). With
MRI, the sensitivity, specificity, accuracy, PPV and NPV for detecting
metastatic lymph nodes on an area-by area basis were 46.2%, 87.9%, 83.9%,
28.6% and 94.0%, respectively; with FDG-PET/CT, the corresponding
values were 69.2%, 90.3%, 88.3%, 42.9% and 96.6%. FDG-PET/ CT
showed higher sensitivity, but the difference did not reach statistical
significance (p=0.250). There were no differences in specificity, accuracy,
PPV and NPV. In the detection of distant metastases, the sensitivity,
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specificity, accuracy, PPV and NPV of FDG-PET/CT were 100%, 93.8%,
92.5%, 62.5% and 100%, respectively. The authors conclude that FDG-
PET/CT showed moderate sensitivity, specificity and accuracy in detecting
primary lesions and lymph node metastases in these patients with uterine
corpus cancer but that it cannot replace surgical staging. The primary benefit
of FDG-PET/CT is its sensitivity in detecting distant metastases. Because of
its high NPV in predicting lymph node metastasis, FDG-PET/CT may also
have advantages in selected patients who are poor candidates for surgical
staging. According to Kitajima et al., of the PET Center, Dokkyo Medical
University Hospital, Mibu, Shimotuka, Tochigi, Japan, histopathology
should be the gold standard for assessing the accuracy of FDG-PET/CT in
detecting pelvic and paraaortic lymph node metastases in patients with
endometrial cancer . Forty patients in clinical stages IA to IIIC underwent
radical hysterectomy, including pelvic lymphadenectomy with or without
paraaortic lymphadenectomy after FDG-PET/CT. Lymphadenectomy
involved removing all visible lymph nodes in the surgical fields. FDG-
PET/CT findings were interpreted by two experienced
radiologists in consensus and compared with histopathological results. The
criterion for malignancy on FDG-PET/CT images was increased radiotracer
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uptake by a lymph node, irrespective of node size. In all 40 patients, the
pelvic lymph nodes dissected included the common iliac, external iliac,
internal iliac and obturator fossa nodes on both sides. In the 34 patients who
also underwent paraaortic lymphadenectomy, the procedure involved
removal of the nodal tissue over the distal vena cava from the level of the
left renal vein to the mid-right common iliac artery, and removal of the
nodal tissue between the aorta and the left ureter from the level of the left
renal vein to the mid-left common iliac artery. Sixty-two pathologically
positive nodes were found in ten patients and, of these, 60 were identified on
the CT component. The overall node-based sensitivity, specificity and
accuracy of FDG-PET/CT for detecting nodal metastases were 53.3%
(32/60), 99.6% (1,419/1,424) and 97.8% (1,451/ 1,484), respectively. The
sensitivity for detecting metastatic lesions was 16.7% (4/24) for those
measuring 4 mm or less in diameter, 66.7% (14/21) for those between 5 and
9 mm, and 93.3% (14/15) for lesions with a diameter of 10 mm or more. The
overall patient-based sensitivity, specificity and accuracy were 50% (5/10),
86.7% (26/30) and 77.5% (31/ 40), respectively. The authors conclude that
although FDGPET/ CT is superior to conventional imaging techniques, it is
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only moderately sensitive in predicting lymph node metastases
preoperatively in patients with endometrial cancer and should not replace
lymphadenectomy (2).
7.3 Ovarian cancer
The risk factors for ovarian cancer have been reviewed by Salehi et al., of
the McLaughlin Center for Population Health Risk Assessment, University
of Ottawa, Ontario, Canada . Although the aetiology of ovarian cancer is
not clear, certain factors are implicated, such as ovulation, gonadotropic and
steroid hormones, germ cell depletion, oncogenes and tumour suppressor
genes, growth factors, cytokines and environmental agents. To compare the
accuracy of combined FDG-PET/CT with that of CT alone in detecting
ovarian carcinoma recurrence, Sebastian et al., of the Department of
Radiology, Massachusetts General Hospital, Boston, MA, USA, compared
53 restaging FDG-PET/CT scans (from 51 patients) with standard diagnostic
CT scans performed in the same patients . Two body imaging radiologists
independently assessed the CT scans; each then teamed with a nuclear
medicine specialist to review the FDG-PET/ CT images. Two teams
conferred for consensus on the presence of disease in the chest, abdomen
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and body overall detected by CT alone and by FDG-PET/CT, using a six
point reader confidence metric to determine accuracy and receiver operating
characteristic (ROC) curves. Reader agreement was compared using kappa.
Recurrence was determined by two gynecological oncologists reviewing
clinical records from time of presentation to at least 13 months (mean 22.7
months) after imaging. Recurrence was based on histopathology in 17% of
cases (9/53). Seventy-two percent of cases (38/53) had recurrence with two
cases showing isolated chest recurrence. The accuracy of FDG-PET/CT
exceeded that of CT for body [92% (49/ 53) vs 83% (44/53)], chest [96%
(51/53) vs 89% (47/53)] and abdomen [91% (48/53) vs 79% (42/53)].
Analysis of ROC curves showed superior performance of FDG-PET/CT
compared to CT alone; this difference was statistically significant for
abdomen and for the body overall (p<0.01). Interobserver agreement was
better for FDG-PET/CT than for CT alone. The authors conclude that FDG-
PET/CT demonstrates greater accuracy and less interobserver variability
than CT alone. In another study, Soussan et al., of the Nuclear Medicine
Department, Rene Huguenin Cancer Research Center, Saint- Cloud, France,
set out to evaluate the impact of integrated FDG-PET/CT on the therapeutic
management of patients in whom ovarian carcinoma recurrence is suspected
because of the presence of increased CA-125 . They examined 29 patients
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(mean age 61 years) initially treated for ovarian carcinoma (FIGO stage I
n=2, stage II n=3, stage III n=21 and stage IV n=3) and presenting with
increased CA-125 (mean 160 IU/mL, range 33–1,930 IU/mL). Each patient
was submitted to a CT and an FDG-PET/CT scan. The impact of the FDG-
PET/CT results on the management of each patient was evaluated by
comparing the therapeutic decision entered in pre- and post-FDG-PET/CT
questionnaires filled in by oncologists. The CT scan was positive in 22/29
patients (76%) and negative in 7/29 (24%). The FDG-PET/CT scan was
positive in 27/29 patients (93%) and negative in 2/29 (7%). Five of the seven
patients with a negative CT scan had a positive FDG-PET/CT scan.
Compared to the CT scan alone, the FDG-PET/CT scan revealed a different
disease distribution in 16 patients (55%; p<0.001), indicating more advanced
disease in 11 patients, more limited disease in four and different
localisations in one. Assessment of the pre- and post-FDG-PET/CT
questionnaires showed a statistically significant change in the decision
reached for ten of the patients (34%, p<0.0001). According to the authors,
the results of this questionnaire-based study show that FDGPET/ CT
imaging allows better restaging than CT and induces a change in clinical
management strategy in over one-third of patients with suspicion of ovarian
carcinoma recurrence, based on the finding of increased CA-125. The
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diagnostic performances of MRI and FDG-PET/CT for the detection of
recurrent ovarian tumour are reported in a study by Kim et al., of the
Department of Radiology and Center for Imaging Science, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea. Thirty-six patients who had had primary cytoreductive surgery
for ovarian carcinoma received both MRI and FDG-PET/CT to evaluate the
presence of tumour recurrence. Recurrent ovarian tumours in the abdomen
and pelvis were classified by site as follows: (1) local pelvic recurrence, (2)
peritoneal lesion, (3) lymph node metastasis and (4) distant metastasis.
Patient-based and lesion-based analyses were retrospectively performed to
detect tumour recurrence. The accuracy of each of these two modalities in
detecting recurrent tumours was compared using the McNemar test.
Histopathological, clinical and radiological follow-up findings revealed
recurrent ovarian tumours in 35 sites in 22 patients: local pelvic recurrence
(n=15), peritoneal lesions (n=14), lymph node metastasis (n=4) and
abdominal wall metastasis (n=2). The patient-based sensitivity and the
accuracy of FDG-PET/CT and MRI in detecting recurrent ovarian tumour
were 73% and 91% (p<0.05), and 81% and 89% (p>0.05), respectively. In
addition, FDG-PET/CT and MRI showed an overall lesion-based sensitivity
of 66% and 86%, respectively (p<0.05). In detecting peritoneal lesions, the
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overall lesion-based sensitivity and accuracy of FDGPET/ CT and MRI for
peritoneal lesions were 43% and 86%, and 75% and 94%, respectively
(p<0.05). The authors conclude that MRI is more sensitive than FDG-
PET/CT for detecting local pelvic recurrence and peritoneal lesions of
recurrent ovarian tumours. Kitajima et al., of the PET Center, Dokkyo
Medical University Hospital, Mibu, Shimotuka, Tochigi, Japan, recently
conducted a study aimed at evaluating the accuracy of FDG-PET/CT with
IV contrast in depicting suspected recurrent ovarian cancer and at assessing
the impact of FDGPET/ contrast-enhanced CT findings on clinical
management, compared with PET/non-contrast-enhanced CT and CT alone.
They studied 132 women previously treated for ovarian cancer. The women
were submitted to FDG-PET/CT consisting of non-enhanced and contrast-
enhanced CT for suspected recurrence. Each investigation was interpreted in
consensus by two experienced radiologists. Lesion status was determined on
the basis of histopathology, radiological imaging and clinical follow-up
lasting longer than 6 months. Patient-based analysis showed that the
sensitivity, specificity and accuracy of FDG-PET/contrast-enhanced CT
were 78.8% (52/66), 90.9% (60/66) and 84.8% (112/132), respectively,
compared to 74.2% (49/66), 90.9% (60/66) and 82.6% (109/132)
respectively for FDG-PET/noncontrast- enhanced CT and 60.6% (40/66),
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84.8% (56/66) and 72.7% (96/132), respectively, for enhanced CT.
Sensitivity, specificity and accuracy values differed significantly among the
three modalities (Cochran Q test: p=0.0001, p= 0.018, and p<0.0001,
respectively). The FDG-PET/contrastenhanced CT findings led to a change
of management strategy in 51 of the 132 patients (39%), whereas the
management approach was affected in 16 patients (12%) diagnosed by
enhanced CT alone and in 3 (2%) diagnosed by FDG-PET/non-contrast-
enhanced CT. From these findings, the authors conclude that integrated
PET/contrast-enhanced CT is an accurate modality for assessing ovarian
cancer recurrence and for guiding appropriate therapeutic changes (2).
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8. Stereotactic body radiotherapy (SBRT) vs volumetric modulated
RapidarcTM radiotherapy (RA-IMRT) in positive lymph-nodes
recurrence of gynaecological malignancies.
8.1 Introduction
Gynaecological malignancies as a cervical, uterine and ovarian cancer,
represent an important cause of morbidity and death in the worldwide
women’s population (1) . In cervical cancer patients, as demonstrated in
several retrospective studies, about 15-30 % of newly clinically diagnosed
have pelvic/para-aortic lymph node involvement (1).  An accurate staging of
the disease at the time of diagnosis is mandatory to choose the appropriate
therapeutic treatment. Local tumor recurrence occurs in 10-20% of patients
after surgical treatment and this number increases to over  50%  if lymph
nodes metastases are present at the diagnosis (13,14).
Endometrial cancer is also a common gynaecological cancer but it is
generally associated with good prognosis and less than 20% of patients have
positive lymph nodes at the time of diagnosis. For these type of patients the
most frequent site of recurrence is the vaginal cuff and the salvage
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radiotherapy (external beams alone or combined with brachytherapy) leads
to excellent results.
Ovarian cancer has a high incidence (75%) of recurrence in the 2 years after
primary treatment, and 50% of the patients will die of their disease (1, 12),
so a strict follow-up is the common practice to detect early relapse. For this
type of tumors CA-125 serum level monitoring is also a common practice to
detect early relapse.
The imaging techniques such as computer tomography (CT) and 18-fluoro-
deoxy-glucose positron emission tomography/CT (18FDG-PET/CT) have
recently shown promising results for staging and follow-up however
18FDG-PET/CT is not yet approved with standard imaging technique (1,
17).
Salvage surgery and radiotherapy play an important role in patients with
isolated lymph node metastases but they are associated to high morbidity
and mortality rates (5).
Recent innovative technologies such as intensity modulated radiotherapy
(IMRT), image-guided radiotherapy (IGRT), volumetric modulated
Rapidarc radiotherapy (RA-IMRT) and stereotactic body radiotherapy
(SBRT) allow to administer higher doses to the  tumor due to the precise
target localization and   accurate dose delivery .
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In this study we described our short preliminary experience using and
comparing RA-IMRT vs. linac based SBRT in the salvage treatment of
isolated lymph node recurrences in patients affected by gynaecological
cancer. We analyzed our preliminary results in terms of local control rate
(LC), acute toxicity and overall survival rate (OS).
8.2Materials and Methods
Study protocol
Comparison of RA-IMRT vs SBRT techniques, LC, acute toxicity and OS
rate, in the treatment of isolated nodal recurrence in patients affected by
gynaecological cancer.
From January 2010 to September 2011, 15 patients affected by isolated
lymph nodes recurrence of gynaecological cancer underwent salvage
radiotherapy treatment after conventional imaging staging with CT and 18-
FDG-PET/CT. Two different radiotherapy techniques were used in this
study: RA-IMRT (RapidarcTM implemented radiotherapy Varian Medical
System, Palo Alto, CA, USA) or SBRT (BrainLAB, Feldkirchen, Germany)
at the European Institute of Oncology, Milan, Italy.
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Patient carateristics
Fifteen patients affected by isolated nodal recurrence of gynaecological
cancer were included in the study. The histological classification was:
ovarian cancer (9 patients), cervix squamous cell carcinoma (4 patients),
endometrial adenocarcinoma (1 patient), uterine tube carcinoma (1 patient).
The mean age at the time of diagnosis was 62.8 years (range 40-79 years). In
all cases previous chemotherapy and/or surgery was administrated and 3
patients received  radiotherapy in the past.
Sixteen nodes were treated: 6 with RA-IMRT and 10 with SBRT.
Five patients underwent CT scan and in all patients 18FDG-PET/CT was
performed for pre-treatment evaluation and staging. In 2 cases this local
treatment was a re-irradiation after a previous  radiotherapy. No patients
received concomitant chemotherapy (table 1).
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Table 1. Patients, tumor and treatment characteristics (N= 15 patients, n=16
nodes)
Characteristics All patientsN=15
Age (years), at the treatment
Mean
Range
62.8
40 - 79
Primary diagnosis (N=15 patients)
Ovarian
Cervical
Endometrial
Uterine tube
9
4
1
1
Previous RT 3*
RT treatment (patients/nodes)
RA-IMRT
SBRT
6/6
9/10
*3 patients received  radiotherapy in the past years, for two of these patients this
treatment (SBRT) was reirradiation for recurrence of disease.
Legend: volumetric modulated Rapidarc radiotherapy (RA-IMRT), stereotactic body
radiotherapy (SBRT)
Radiotherapy techniques and volumes
RA-IMRT
Six patients (and 6 nodes) underwent RA-IMRT treatment. The site of the
nodes was: chest wall (one patient), hepatic hilus (one patient), common
iliac lymph node (one patient), pararectal (one patient), presacral (one
patient), perigastric (one patient).
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The simulation procedure with contrast medium CT scan was performed
with  3 mm slicing. Patients were scanned in supine position with Combifix
immobilization device. The simulation CT scan was integrated either with
18FDG-PET/CT for gross tumour volume (GTV) delineation . A mean
margins of 7.6 mm (range 7-8 mm) in all direction were then added to GTV
to create planning target volume (PTV). The organs at risk including urinary
bladder, rectum, colon and  small bowel, kidneys, liver, stomach, lung,
spinal cord and cauda equina were drawn.
PET image interpretation
Image readout was performed on a Xeleris Workstation (General Electric
Medical Systems), which allows visualization of 18FDG-PET, CT, and
fused 18FDG-PET/CT sections in transverse, coronal, and sagittal planes.
18FDG-PET/CT images were interpreted by an experienced nuclear
medicine physician, who had knowledge of all clinical and instrumental
data, in collaboration with an experienced radiation oncologist.
The presence of pathological 18FDG uptake was indicated when tracer
uptake was increased relative to uptake in surrounding tissue and normal
structures, excluding physiological bowel, urinary activity and non specific
genital uptake in young women.
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In the case of pathological 18FDG uptake, its exact anatomic location was
indicated on the basis of integrated CT findings.
The uptake of the primary tumor was always reported.
The diagnosis of pathologic lymph node on 18FDG-PET/CT images was
based on the presence of focal increased FDG uptake on PET images,
corresponding to lymph nodal chains, on CT images.
Such nodes were referred always as positive, independently of their size on
CT.
RA-IMRT: Dose prescription
The mean total dose delivered with conventional dose of 1.8-2 Gy/fraction
was 54.3 Gy (range 50-60 Gy): 50 Gy (two patients), 54 Gy (one patient),
55.8 Gy (one patient), 56 Gy (one patient), 60 Gy (one patient). The mean
number of fractions was: 27.6 fractions (range 25-31) and the mean overall
treatment duration was 40.5 days (range 36-45) (table 2).
The dose was prescribed to the PTV volume. RapidArc (RA) plans was
generated using two coplanar arcs of 360° optimized simultaneously with a
beam energy of 6 MV. The RA technique uses continuous variation of the
instantaneous dose rate, multileaf collimator (MLC) leaf positions and
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gantry rotational speed to optimize the dose distribution. The collimator
angle was kept fixed and set to 20° for all patients.
The dose calculations and optimizations were performed using the Eclipse
treatment planning system (version 8.6) for a Trilogy equipped with the
Millennium MLC 120 leaves (leaf width at isocenter of 5 mm in the central
20 cm part of the field, 10 mm in the outer 2x10 cm). The maximum dose
rate was set to 600 MU/min. Dose calculation was performed with the AAA
algorithm using a grid of 2.5 mm.
RA-IMRT: Treatment verification
Based on the institutional set-up verification protocols, patient position
verification was performed before each treatment session by means of kV
cone beam CT (CBCT) system integrated in the machine.
Any variation of set-up was then controlled and the institutional action level
protocols were always applied.
SBRT
Nine patients (10 nodes) underwent  SBRT. The site of the nodes was: 7
para-aortic (6 patients), supracalvicular (one patient), cardiophrenic (one
patient), lung hilar lymph node (one patient). The mean dose delivered was:
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27.4 Gy (range 12-40 Gy): 12 Gy/3 fractions (one patient), 24 Gy//4
fractions (one patient), 24 Gy/3 fractions (2 patients), 26 Gy/4 fractions (one
patient), 30 Gy/3 fractions (2 patients), 32 Gy/4 fractions (2 patients), 40
Gy/4 fractions (one patient). The mean overall treatment duration was 6.5
days (range 5-8 days). All patients received prophylactic antiemetic
treatment with dexamethasone. For SBRT, Brainscan treatment planning
system (v. 5.31, BrainLAB, Feldkirchen, Germany) was used. Simulation
CT scan with no contrast medium was performed (18FDG-PET/CT was
employed for a better target volume definition). Treatment plans consisted of
1-3 noncoplanar 6-MV conformal dynamic arcs obtained with the micro-
multileaf collimator m3 (BrainLAB). Patients were immobilized in a
vacuum pillow fixed on a carbon-fiber tray in supine position. All patients
were also positioned using the optoelectronic localisation system (Exac Trac
v.5.0.2. BrainLAB) (table 2).
SBRT: volumes and dose prescription
The GTV was contoured on the simulation CT scan. Heterogeneous margins
were added to GTV in order to create PTV. Mean 5.3 mm (range 5-6 mm)
margin was applied for cranio-caudal, latero-lateral and antero-posterior
direction, respectively. Dose volume histograms (DVH) were calculated for
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PTV and organs at risk (OAR). Total SRT doses ranged from 12 to 40 Gy
given in 3-4 fractions. These different fractionated regimens of total dose
was adjusted to the individual patient characteristics (tumor size, doses to
organs at risk, re-irradiation). The dose was prescribed at the isocenter (at
least 95% of PTV received at least 90% of the prescribed dose). The organs
at risk were: liver, stomach, kidneys, oesophagus, lung, spinal cord, heart,
trachea, brachial plexus,  and the well-established normal tissue tolerance
doses were respected (8).
SBRT: Treatment verification
The patient set-up was verified with an electronic portal imaging device
(Portal Vision, Varian, Palo Alto USA) comparing a couple of orthogonal X-
ray images with the corresponding digitally reconstructed radiographs. The
different bone structures were used as anatomical landmarks.
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Table 2. Radiotherapy Techniques
Technique Site/n° Dose Gy(Gy/fraction)
Number
fraction Days RT
RA-IMRT
Chest wall 1 60(2) 30 45
Hepatic hilus 1 50(2) 25 36
Common iliac lymph-node 1 50(2) 25 36
Pararectal 1 55.8(1.8) 31 44
Presacral 1 56(2) 28 39
Perigastric 1 54(1.8) 30 43
SBRT
Para-aortic 7 25(8)^ 3^ 5^
Supraclavicular 1 24(6) 4 8
Cardiophrenic 1 30(10) 3 5
Lung hilar lymph node 1 32(8) 4 8
^median dose Gy (Gy/fraction), median number fraction and median days RT
Legend: volumetric modulated Rapidarc radiotherapy (RA-IMRT), stereotactic body
radiotherapy (SBRT)
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Fig. 10 (A e B)
Rapidarc IMRT treatment planning
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Fig. 11
Example of SBRT treatment planning
8.3 Results
Toxicity evaluation
Radiation Therapy Oncology Group/European Organisation for Research
and Treatment of Cancer (RTOG/EORTC) criteria were used to evaluate
treatment toxicity (ref). Acute toxicity was evaluated during radiotherapy
treatment and during follow-up. In the RA-IMRT patients, gastrointestinal
(GI) acute toxicity was: G0 (4 patients), G1 (2 patients); particularly 2
patients developed nausea and vomiting controlled with prophylactic
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antiemetic treatment with ondansetron in oral administration. For SBRT
patients: the acute toxicity was G0 (8 patients) and G1 (one patients). No
haematological acute toxicity was observed in all patients (table 3).
Survival and local control
The patients were controlled with radiological imaging (CT scan after 40
days and CT or 18FDG-PET/CT ) after 3 months and during the follow-up),
clinical evaluation and only in ovarian patients CA-125 serum level was
controlled.
After a mean follow-up of 5 and 4.8 months (range 2-10 /1-13.3 months) for
RA-IMRT and SBRT patients, 13/15 patients were evaluated (in 2 patients
the response evaluation has not been yet performed).
Local response:
The local control rate ( the complete response of pathological disease after
radiotherapy treatment) evaluated in 13/15 patients for a total number of 14
nodes (5/6 patients and nodes (RA-IMRT) and 8/9 patients, 9/10 nodes
(SBRT) was 92.8% (5/5 nodes = 100% vs. 8/9 nodes = 88.9% for RA-IMRT
and SBRT respectively).
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Pattern of failure:
At the time of the analysis, October 2011, six patients are alive with no
evidence of disease (2/5 = 40% and 4/8 = 50% patients RA-IMRT vs SBRT,
respectively) , six patients are alive with clinically evident disease in other
sites (2/5 = 40% and 4/8 = 50% patients RA-IMRT vs SBRT, respectively ),
one patient died for systemic progression of disease, one patient was lost of
follow-up and one patient was not evaluable at this time.
The overall survival at October 2011 was 92.3 % ( particularly was 80% for
RA-IMRT and 100% for SBRT).
Table 3. Outcome
Patients/nodes RA-IMRT SBRT
Acute toxicity (for patients)
Yes
5
2
8
1
Follow-up duration (months)
Mean (range) 5 (2-10) 4.8 (1-13.3)
Response to treatment
Radiological ( CT) and/or FDG-PET/CT :
Evaluable
Local control (for nodes)
Non local control
Non evaluable (NE)
Complete response (for patients)
Progression of disease in other sites
Died for progression of disease
Non evaluable (NE)
Overall survival rate (for patients)
5
5 (100%)
0
1
2 (40%)
2 (40%)
1
1
4 (80%)
9
8 (88,9%)
1
1
4 (50%)
4 (50%)
0
1
8 (100%)
Legend: computer tomography (CT) , 18-fluoro-deoxy-glucose positron emission
tomography/CT (18FDG-PET/CT), volumetric modulated Rapidarc radiotherapy (RA-
IMRT), stereotactic body radiotherapy (SBRT)
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8.4 Discussion
Our study showed the feasibility of the radiotherapy employing RA-IMRT
and SBRT for isolated single lymph nodes recurrent in gynaecological
cancer.
In our experience RA-IMRT it is a better technique when the lymph nodes
are in the central abdominal - pelvis and when a very high organ and
respiratory motion must be checked before treatment with a CBCT. If the
lymph nodes are near to bone structures and if it is not present a very high
organ motion the use of a 3D kV system for the position control (ExaTrac
BrainLAB) is a very good solution. However our investigation is ongoing
employing dose escalation and hypofractionation protocols.
The incidence of isolated paraaortic lymph nodes (PALN) metastases is
1.7%- 12% after definitive treatment of carcinoma of the uterus (5 The
standard radiation dose delivered to PALN metastases is 45-46 Gy (5) but
this dose level would not be considered curative. In fact, it is responsible for
a significant portion of treatment failures for advanced cervix patients (8).
The OS with salvage radiotherapy treatment alone for PALN recurrences is
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0-19% (5) but these numbers may have improved with use of concurrent
chemotherapy (5, 15, 16). With the use of IMRT it is possible to enhance the
dose delivered to the GTV and PTV maintaining the dose to the critical
structures at acceptable levels. The escalation doses of 59.4 Gy to the GTV
and 50.4 Gy to the CTV are considered appropriate at this time (9).
However also in consideration of site of recurrence it is possible to use a
different techniques as IMRT, IGRT and SBRT. With the use of IMRT it is
possible to deliver two or plus levels of doses in the same time of treatment
with the simultaneous integrated boost (SIB): Ahmed et al. (10) reported the
efficacy and the ability to delivered an escalation doses in the positive lymph
nodes with IMRT particularly the dose to the GTV was escalated to 60 Gy in
2.4 Gy/fraction (the linear-quadratic model with an α/β ratio of 10 was 63
Gy at 1.8 Gy/fraction).
In the study of Choi et al. (5), Cyberknife-SBRT was compared to the
treatment delivered with use to conventional radiotherapy modalities in 30
patients affected by PALN metastases from uterine cervical and corpus
cancers. The patients received a dose of 27-45 Gy of external beam
radiotherapy followed by SBRT boost or exclusive SBRT alone of 33-45 Gy
in 3 fractions (equivalent of dose of  58-94 Gy). The PTV was created
adding a margin of 2 mm to GTV. Four-year OS and LC rates were 50.1%
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and 67.4%, respectively.
Higginson et al. (8) reported 7 patients treated with SBRT with Cyberknife
for isolated PALN recurrences (cervix, endometrial, ovarian cancer), 4/7
patients received 45-46 Gy of conventional radiotherapy in addition to
radiosurgery. Dose ranged from 30 Gy/5 fractions to 20 Gy/4 fractions. At
10,18 and 19 months of follow-up 3 patients have no evidence of disease
(NED).
Guckenberger et al. (6) evaluated outcome of conformal radiotherapy
followed by a boost with SBRT for locally recurrent cervical and
endometrial cancer. The standard dose prescribed was 50 Gy/25 or 28
fractions and 15 Gy/3 fraction respectively. The LC rate was 81% at 2 and 3
years.
SBRT has been used for gynaecological malignancies in the treatment of
macroscopic pelvic and para-aortic lymph nodes and oligometastatic disease
but it might useful to consider the internal organ motion and the consequent
target motion. In these cases IGRT with CBCT could be of value.
Kim et al. (7) evaluated the positioning accuracies of two image-guided
localisation system, ExacTrac (BrainLAB) and On Board Imager (OBI)
from Trilogy system (Varian Medical System) but their study was based on
a rigid phantom.
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8.5 Conclusion
Our preliminary results showed that RA-IMRT and SBRT are an excellent
local therapy for isolated lymph node recurrence of gynaecological cancer
with a good toxicity profile and local control rate, even if any long term
survivors would be expected. New treatment modalities like Cyberknife are
also being implemented. In our experience we found that RA-IMRT it is the
best technique when the lymph nodes are in the central abdominal -pelvis
and when a very high organ and respiratory motion must be checked before
treatment with a image guided radiotherapy such as CBCT.
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9. Conclusion
SBRT is an emerging technology with the potential to benefit cancer patients
in many ways. As SBRT is implemented more widely throughout the field,
radiation oncologists are encouraged to participate in formal clinical trials
whenever possible so that the knowledge base concerning the strengths and
limitations of SBRT can continue to broaden. Outside of formal clinical trial,
the same level of discipline and quality assurance measures should be
applied so that patients may receive this novel, technically complex
treatment as safely and effectively as possible (19).
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